(Q83234382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

main subject

phase I clinical trial

1 reference

1 reference

1 reference

head and neck carcinoma

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Johnny Kao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Eric M Genden

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Chien-Ting Chen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Michael Rivera

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kryztof Misiukiewicz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Vishal Gupta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Vivek Gurudutt

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Marita Teng

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Stuart H Packer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

18 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

3173-3181

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Prognostic factors for survival after salvage reirradiation of head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Skin cancer of the head and neck with perineural invasion: defining the clinical target volumes based on the pattern of failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Salvage re-irradiation for recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25786

7 January 2021

Identifiers

DOI

10.1002/CNCR.25786

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21246519%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference